ABSTRACT
Following a Traditional Mediterranean diet (TMD) decreases cardiovascular risk. However, its anti-thrombotic effects are unexplored. We aimed to assess whether this dietary pattern improved thrombosis-related biomarkers in high cardiovascular risk subjects. In 358 random PREDIMED Study volunteers (Prevención con Dieta Mediterránea), we assessed: 1) 1-year effects of a TMD, enriched in virgin olive oil (TMD-VOO; N=120) or nuts (TMD-Nuts; N=119) versus a low-fat diet (N=119), on thrombosis biomarkers; 2) the differences between individuals with greater TMD compliance increments (≥3 adherence score points) and those with compliance decrements; and 3) associations between 1-year changes in key TMD food groups and thrombosis signals. TMD-VOO and TMD-Nuts attenuated pro-thrombotic status (−5.1% –P=0.045– and −5.8% –P=0.025–, respectively). TMD-VOO decreased HDL-bound α1-antitrypsin levels (HDL pro-inflammatory/pro-thrombotic properties, −6.3%, P=0.034) and increased HDL platelet activating factor-acetylhydrolase activity (+7.5%, P=0.044). TMD-Nuts diminished non-esterified fatty acid levels (−10.3%, P=0.022). Individuals with greater TMD adherence increments presented decreases in their pro-thrombotic status (−9.5%, P=0.032), fibrinogen levels (−9.1%, P=0.030), and non-esterified fatty acid concentrations (−18.1%, P=0.011). Only the low-fat diet was associated with increased platelet factor-4 concentrations (P=0.012) and thrombin activation (higher prothrombin factor1+2 levels, P=0.003) versus baseline. Finally, in the secondary analyses, nut intake increases were associated with antithrombin increments, fruit and vegetable consumption increases were linked to decreases of thrombin activation, and processed meat intake decrements were related to increases in antithrombin and nitrite + nitrate levels (P<0.05). Summarizing, TMD and some of its typical food items were associated with improved thrombosis biomarkers in high cardiovascular risk individuals.
KEY POINTS
Following a Mediterranean diet improves thrombosis-related biomarkers in high cardiovascular risk individuals
Competing Interest Statement
X.P. reports personal fees from Abbott, Esteve, Lacer, Rubio, and Sanofi outside the submitted work. J.S.-S. reports to be a board member and grants from Nut and Dried Fruit; personal fees from Aguas Font Vella Lanjarón, Danone S.A., and Instituto Danone; grants from Eroski Distributors; and non-financial support from Nuts for Life outside the submitted work. F.A. reports personal fees from Menarini and AstraZeneca outside the submitted work. E.R. reports personal fees and non-financial support from Merck, Sharp & Dohme; grants, personal fees, and non-financial support from California Walnut Commission; grants and personal fees from Sanofi; personal fees and non-financial support from Ferrer International; and grants from Pfizer outside the submitted work. R.E. reports grants from Bicentury SA, Cerveza y Salud, Grand Fountaine, and Novartis SA; and personal fees from Brewers of Europe, FIVIN, Fundación Cerveza y Salud, Lilly Laboratories, and Wine and Culinary International Forum outside the submitted work. The rest of the authors have nothing to disclose.
Clinical Trial
ISRCTN35739639
Funding Statement
This work was supported by grants of Instituto de Salud Carlos III [OBN17PI02, PIE14/00045_INFLAMES, CB06/03/0019, CB06/03/0028, CD17/00122 (A.H.), and JR17/00022 (O.C.)], and Agència de Gestió d'Ajuts Universitaris i de Recerca (2017 SGR 222). The sponsors of this study are public/nonprofit organizations that support science in general and had no role in gathering, analyzing, or interpreting the data. CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN) is an initiative of the Instituto de Salud Carlos III, Madrid, Spain.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
2
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos